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Brugada syndrome (BrS) is a rare clinical condition char-acterized by atypical right bundle branch block and 
elevated ST segments in right precordial leads in the absence 
of structural heart disease.1 Diagnosis is sometimes difficult 
because the same pattern can be seen in patients with other 
cardiac diseases, such as arrhythmogenic right ventricular 
cardiomyopathy, myocardial infarction, and others.2 Hence, 
additional clinical features, including documented ventricular 
fibrillation, polymorphic ventricular tachycardia, a family his-
tory of sudden cardiac death at <45 years of age, coved-type 
ECGs in family members, syncope, nocturnal agonal respira-
tion, or febrile-initiated triggers, aid in the diagnosis.3–7
Clinical Perspective on p 184
BrS is inherited as an autosomal-dominant trait, with incom-
plete penetrance.8 To date, mutations in 9 genes encoding ion 
channel subunits have been associated with BrS (SCN5A, SCN1B, 
SCN3B, CACNA1C, CACNB2B, CACNA2D1, KCNJ8, KCND3, 
and KCNE3).9–12 In addition, gene products affecting cardiac ion 
currents have been linked to or suggested as susceptibility genes 
(GPD1L, MOG1).13,14 The majority of these mutations have been 
reported in the SCN5A gene encoding the cardiac sodium channel 
NaV1.5 which is the molecular basis of INa, the current underlying 
the depolarization (phase 0) of the cardiac action potential.15
In this study, we identified novel mutations in SCN5A in 
2 independent families with BrS and investigated how these 
mutations affected NaV1.5 channel function.
Methods
Study Subjects
The study conforms to the principles outlined in the Declaration of 
Helsinki and was approved by the Institutional Review Board of the 
University of California San Francisco. All included patients gave 
written informed consent.
Mutation Screening
Genetic screening of the probands and family members was per-
formed at Gene Dx (Gaithersburg, MD) analyzing the genes 
SCN5A, CACNA1C, CACNB2, GPD1L, KCNE3, SCN1B, and 
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Background—Brugada syndrome is a heterogeneous heart rhythm disorder characterized by an atypical right bundle block 
pattern with ST-segment elevation and T-wave inversion in the right precordial leads. Loss-of-function mutations in SCN5A 
encoding the cardiac sodium channel NaV1.5 are associated with Brugada syndrome. We found novel mutations in SCN5A 
in 2 different families diagnosed with Brugada syndrome and investigated how those affected NaV1.5 channel function.
Methods and Results—We performed genetic testing of the probands’ genomic DNA. After site-directed mutagenesis and 
transfection, whole-cell currents were recorded for NaV1.5 wild type and mutants heterologously expressed in Chinese 
hamster ovary-K1 cells. Proband 1 had two novel NaV1.5 mutations: NaV1.5-R811H and NaV1.5-R620H. The NaV1.5-
R811H mutation showed a significant loss of function in peak Na+ current density and alteration of biophysical kinetic 
parameters (inactivation and recovery from inactivation), whereas NaV1.5-R620H had no significant effect on the current. 
Proband 2 had a novel NaV1.5-S1218I mutation. NaV1.5-S1218I had complete loss of function, and 1:1 expression of 
NaV1.5-wild type and NaV1.5-S1218I mimicking the heterozygous state revealed a 50% reduction in current compared 
with wild type, suggesting a functional haploinsufficiency in the patient.
Conclusions—NaV1.5-S1218I and R811H are novel loss-of-function mutations in the SCN5A gene causing Brugada 
syndrome. (Circ Arrhythm Electrophysiol. 2013;6:177-184.)
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SCN3B. The control group consisted of 400 healthy subjects of 
white and black ancestry.
Mutagenesis
The cDNA encoding hNaV1.5 refers to isoform 2 (GenBank Acc. 
No. NM_000335) and is also known as hH1c,16 that is, it lacks 
Q1077. The nomenclature of the variants refers according to con-
ventions to isoform 1 (NM_198056).17 The point mutations R620H 
(c.1859G>A), R811H (c.2432G>A), and S1218I (c.3653G>T) in 
NaV1.5 were introduced using mutated oligonucleotide extension (PfuTurbo Polymerase; Stratagene, La Jolla, CA) from the plasmid 
template hNaV1.5 in pcDNA3.1, digested with DpnI (Fermentas, St. 
Leon-Roth, Germany) and transformed into Escherichia coli XL1 
Blue cells. All plasmids were verified by complete DNA sequencing 
of the cDNA insert (Macrogen Inc, Seoul, Republic of Korea).
Cell Culture and Transfections
Chinese hamster ovary-K1 cells were kept in DMEM (University 
of Copenhagen, Denmark) supplemented with 10% FCS (GIBCO, 
Invitrogen, Carlsbad, CA) and 40 mg/L l-proline at 37°C in 5% CO2. 
Cells were transfected with 2 μg hNaV1.5; in coexpression experi-
ments, wild type (WT) and mutants were transfected in a 1:1 molar 
ratio. Transfections were performed using Lipofectamine and Plus 
reagent (GIBCO, Invitrogen) according to the manufacturer’s instruc-
tions. Enhanced green fluorescent protein (0.2 μg) was included to 
identify transfected cells.
Electrophysiology
Currents were recorded 2 to 3 days after transfection using a 
MultiClamp 700B amplifier and MultiClamp Commander (Axon 
Instruments, Molecular Devices, Biberach an der Riss, Germany). 
Cells were superfused with a solution containing the following (in 
mmol/L): 130 NaCl, 5 KCl, 1.8 CaCl2, 1.0 MgCl2, 2.8 Na-acetate, 
10 HEPES, and 10 glucose, pH=7.3 with NaOH. Patch pipettes were 
fabricated from borosilicate glass capillaries (Module Ohm, Herlev, 
Denmark) and had resistances between 1.5 and 2 MΩ when filled 
with pipette solution (in mmol/L): 10 KCl, 105 CsF, 10 NaCl, 10 
HEPES, 10 EGTA, and 5 TEA-Cl, pH=7.2 with CsOH. Electronic 
compensation of series resistance to 70% to 85% was applied to 
minimize voltage errors. All analog signals were acquired at 10 to 
50 kHz, filtered at 6 kHz, digitized with a Digidata 1440 converter 
(Axon Instruments), and stored using pClamp10 software (Axon 
Instruments). All recordings were made at room temperature (20°C 
–22°C). Data were analyzed using pClamp10 software (Axon 
Instruments) and Prism (GraphPad Software, La Jolla, CA).
Data Analysis
Mean±SEM values are shown; statistical significance (P<0.05) was 
evaluated by 1-way ANOVA, followed by Student–Newman–Keuls 
post-test or by an unpaired Student t test. Because of the relatively 
low sample size, significance was confirmed by a Mann–Whitney 
rank-sum test.
Results
Clinical Characterization
Proband 1 (Figure 1): The patient is a 44-year-old white man 
of Italian ancestry with history of recurrent episodes of syn-
cope. He was first admitted in February 2010 after an episode 
Figure 1. Clinical and genetic information of proband 1. A, ECG of proband. B, Pedigree for the family is shown (circles=women; 
squares=men) with phenotypic and genotypic information where available. The half-filled color in black indicates R811H mutation carrier, 
whereas the half-filled color in gray indicates R620H mutation carrier. The arrow marks the patient diagnosed with Brugada syndrome 
(proband). C, Mutation c.1859G>A resulting in p.Arg620His. D, Mutation c.2432G>A resulting in p.Arg811His. E, Topological position of the 
identified mutations shown in red (top, R620H; bottom, R811H). DI–DIV denotes the 4 homologous domains of the NaV1.5 channel.
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of rapid ventricular tachycardia requiring direct-current shock. 
The ECG was characteristic of the Brugada pattern with a PR 
interval measuring 222 ms, QRS interval measuring 158 ms, 
and QT
c
 interval measuring 416 ms. He had an implantable 
cardioverter-defibrillator. He was readmitted 6 months later 
with a febrile illness attended by recurrent ventricular tachy-
cardia and had a total of 2 shocks en route to our emergency 
facility. He is currently treated with quinidine and theophyl-
line and remains stable.
The family history revealed a history of sudden death of 
one paternal uncle at 49 years of age and another at 36 years 
of age, together with the sudden death of a female cousin at 36 
years of age. The proband’s father had an ECG showing the 
type I Brugada pattern and was asymptomatic. The proband’s 
mother had a normal ECG and no family history suggestive 
of BrS. The proband’s brother was asymptomatic and had a 
normal ECG (PR interval, 186 ms; QRS interval, 98 ms; and 
QT
c
 interval, 431 ms).
Proband 2 (Figure 2): The patient is a 33-year-old white 
man (Swedish and German ancestry) with history of recur-
rent syncope that occurred both at rest and with exercise (yoga 
class of moderate intensity). He had a syncopal episode in 
December 2009 and underwent an electrophysiology study at 
another hospital and had inducible atrial flutter that was suc-
cessfully ablated. At least 1 ECG showed a typical Brugada 
pattern with a PR interval measuring 297 ms, QRS interval 
measuring 125 ms, and QT
c
 interval measuring 400 ms. A 
repeat electrophysiology study at our medical center showed a 
His-ventricular interval  of 79 ms and no inducible ventricular 
tachycardia. He had an implantable cardioverter-defibrillator. 
Family history revealed sudden death of his maternal grand-
mother (who had the Brugada pattern on ECG with a PR inter-
val measuring 204 ms, QRS interval measuring 164 ms, and 
QT
c
 interval measuring 455 ms) and a maternal great uncle at 
60 years of age and history of repeated syncope in a maternal 
great uncle’s brother. The proband’s father had an ECG that 
shows a normal sinus rhythm and left anterior fascicular block 
(PR interval, 182 ms; QRS interval, 120 ms; and QT
c
 inter-
val, 463 ms). The proband’s mother had the Brugada pattern 
with a PR interval measuring 218 ms, QRS interval measur-
ing 102 ms, and QT
c
 interval measuring 434 ms. His brother 
had the coved-down Brugada pattern (PR interval, 246 ms; 
QRS interval, 122 ms; and QT
c
 interval, 389 ms), as well as 
an abnormal procainamide challenge, and underwent implant-
able cardioverter-defibrillator implantation.
Mutation Screening
Direct DNA sequencing of the probands’ DNA revealed 
novel mutations. Proband 1 is compound heterozygous for 
2 novel variants, c.1859G>A and c.2432G>A, leading to 
amino acid changes R620H and R811H, respectively. The 
variant R811H, which resides in the fourth transmembrane 
segment of DII was inherited from the father, the side of his 
family where the other BrS relatives are located, whereas 
Figure 2. Clinical and genetic information of proband 2. A, ECG of proband. B, Pedigree for the family is shown with phenotypic and 
genotypic information, symbols as in Figure 1. Half-filled color in black indicates S1218I mutation carrier. C, Mutation c.3653G>T result-
ing in p.Ser1218Ile. D, Topological position of the identified mutation S1218I shown in red. DI–DIV denotes the 4 homologous domains of 
the NaV1.5 channel.
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the mother carried R620H, which is located in the D1–DII 
linker region (Figure 1C–1E). His brother carries the R811H 
variant but not the R620H variant. His twin daughters carry 
the R620H variant.
Proband 2 is heterozygous for a novel SCN5A mutation, 
c.3653G>T, leading to an amino acid substitution S1218I. 
His mother and brother also carried the S1218I mutation. No 
other variants likely to contribute to disease were found. The 
mutation resides in the transmembrane segment S1 of domain 
III (Figure 2C and 2D)
All amino residues found to be mutated in this study were 
highly conserved among mammalian species. The novel vari-
ants were absent in the control group of 400 healthy subjects 
of white and black ancestry.
Electrophysiological Characterization of  
NaV1.5-R811H and R620H
NaV1.5-WT or NaV1.5-R811H was expressed in Chinese ham-
ster ovary-K1 cells. Both WT and R811H channels exhibited a 
fast activating and inactivating current (Figure 3A). However, 
R811H had a significantly reduced peak current density (Fig-
ure 3B). Double exponential fits to the current decay showed 
that τfast was significantly slower for R811H (Figure 3C). The 
relative weight of the pre-exponential factors for τfast was cal-
culated (Figure 3D), showing that the relative contribution of 
the fast component was not significantly different between 
R811H and WT.
Steady-state activation curves were calculated by nor-
malizing the currents shown in Figure 3 to (V
m
−EK). The 
half-maximal voltage V1/2 of steady-state activation was not 
affected by the R811H mutation, with V1/2=−32.7±0.2 mV 
(n=7) for WT and V1/2=−33.3±0.4 mV (n=7) for R811H 
(Figure 4). Steady-state inactivation was addressed by 
a prepulse–pulse protocol, and representative traces are 
depicted in Figure 4A. For WT, the V1/2 of inactivation was 
−69.5±0.2 mV (n=7) and for R811H it significantly shifted 
to V1/2=−77.9±0.2 mV (n=7; P=0.049). This negative shift 
in V1/2 of inactivation would further contribute to a loss-of-
function phenotype for R811H.
Recovery from inactivation of WT and R811H was 
addressed by a 2-pulse protocol using increasing interpulse 
intervals at −120 mV (Figure 5). At both potentials, the recov-
ery of R811H was significantly slower, with τ=2.65±0.16 ms 
for WT (n=10) and 5.44±0.44 ms for R811H (n=7; P=0.0359), 
which may further exacerbate the phenotype.
The electrophysiological phenotype of NaV1.5-R620H 
was addressed using a similar approach as for NaV1.5-
R811H (Figure 6). R620H peak currents were similar to 
WT (Figure 6A and 6B), and none of the kinetic parameters 
addressed deviated from that of WT (data not shown).
To rule out that the NaV1.5-R620H variant could 
modify the biophysical properties observed for the R811H 
mutation, we mimicked the compound heterozygosity seen 
in the patient and coexpressed the mutant proteins in a 1:1 
molar ratio (Figure 7). Coexpression of NaV1.5-R811H and 
R620H resulted in a 52% reduction in peak current density 
at −25 mV compared with WT, whereas R811H alone 
resulted in a 57% reduction compared with WT, suggesting 
that the R620H variant does not affect the biophysical 
properties of R811H.
Electrophysiological Characterization of  
NaV1.5-S1218I
NaV1.5-WT or NaV1.5-S1218I was expressed in Chinese 
hamster ovary-K1 cells (Figure 8). WT channels produced 
robust currents; in contrast, S1218I showed a complete loss of 
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Figure 3. Electrophysiological character-
ization of R811H. A, Representative whole-
cell current recordings for NaV1.5 wild type 
(WT; n=9) and R811H (n=7) transiently 
expressed in Chinese hamster ovary-
K1 cells. Currents were activated by the 
depicted voltage-clamp protocol. B, Peak 
current density plotted as a function of volt-
age, demonstrating a reduction in current 
for R811H. C, Double-exponential func-
tions were fitted to the current decay, and 
the resulting time constants (τslow and τfast) 
are shown as a function of voltage. D, The 
relative weight of the pre-exponential factor 
for τfast.
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function. For WT and S1218I expressed in a 1:1 ratio to mimic 
the heterozygote state of the patients, peak current density was 
reduced by ≈50%, suggesting that the S1218I mutation does 
not affect WT channels and the phenotype of the patients is 
because of haploinsufficiency.
Steady-state activation and inactivation were addressed as 
described for NaV1.5-R811H, and as expected, no significant 
difference was observed when comparing WT/S1218I with 
WT. Similarly, no difference was found in time-dependent 
recovery from inactivation for WT/S1218I to WT (data not 
shown).
Discussion
Mutations in SCN5A have been implicated in several inher-
ited arrhythmogenic cardiac syndromes, including long-QT 
syndrome (type 3), BrS (type 1), progressive cardiac conduc-
tion disease, atrial fibrillation, and dilated cardiomyopathy.18 
The functional characterization of SCN5A mutations and 
polymorphisms has important implications for the under-
standing of genotype–phenotype correlations—concordance 
and discordance—seen in BrS families. Here, we report novel 
mutations in SCN5A in 2 probands with BrS, which cosegre-
gated with the BrS phenotype, and that we characterized in a 
heterologous mammalian expression system.
Proband 1 had an NaV1.5 compound heterozygous (trans 
mode) for R811H and R620H mutations. In silico analysis 
(PolyPhen-2)19 predicted the SCN5A R620H to be benign, 
while SCN5A R811H to be possibly damaging. Family his-
tory supported that R811H was likely to be pathogenic, while 
R620H was likely benign. The proband’s brother who only 
carried R811H mutation is asymptomatic and has no Brugada 
pattern on his ECG, whereas the proband’s father who only 
carried R811H mutation is asymptomatic but has a Brugada 
pattern on his ECG. Although the R620H was likely benign 
when inherited without the R811H, having both the R811H 
and R620H mutations may have produced the abnormal phe-
notype with BrS. This would not explain the other sudden 
deaths in the paternal family because the R620H was inherited 
from the proband’s mother.
NaV1.5 R811H is a novel mutation that occurs in the DII–
S4 transmembrane domain of the NaV1.5 channel protein, is 
not detected in ≈400 normal control chromosomes of white 
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protocol from a holding of −120 mV. A, Representative recordings. B, The fraction of recovered current was plotted as a function of inter-
pulse interval, and single exponential functions were fitted to the data.
Figure 4. Activation and steady-state inactivation relationship for 
NaV1.5 wild type (WT; n=7) and R811H (n=7). Activation curves were 
calculated by normalizing the currents shown in Figure 3 to (Vm−EK). A, 
Steady-state inactivation was determined using the protocol shown 
in the inset. Representative recordings are shown. B, Peak currents at 
the −20 mV step were normalized and plotted against the conditioning 
potential, and Boltzmann equations were fit to the data points.
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and black ancestry, and involves a highly conserved amino 
acid R811 throughout evolution. Mutations affecting sur-
rounding codons (R808P and L812P) have been reported to 
be associated with BrS.17 The functional studies of NaV1.5 
R811H in a heterologous expression system suggested that 
this mutation decreases the peak Na+ current density con-
ferred by NaV1.5, increases fast and slow Na+ current decay 
time constants, displays a decreased depolarizing shift in 
voltage dependence of inactivation in the steady-state inac-
tivation recordings, and slows recovery from inactivation 
compared with WT.
In contrast, NaV1.5 R620H is a novel mutation in the 
cytoplasmic linker between DI and DII domains, with no 
gating kinetic defect and no change in the peak Na current 
density compared with WT. A recent study suggested that 
the domain I–II linker might be involved in stabilizing the 
fast inactivation of NaV1.5 channels.20 A mutation affecting 
the same amino acid, R620C, has been reported in asso-
ciation with long-QT syndrome, yet no electrophysiological 
characterization was performed in that study.17 Mutations 
affecting neighboring codons (G615E and L619F) have 
been reported in patients with BrS.17 However, in our experi-
ments, R620H did not affect NaV1.5 function. In line with in 
silico prediction and family history, coexpressing the 2 vari-
ants R620H and R811H mimicking the heterozygous state 
of the proband rendered a synergistic interaction between 
them unlikely.
Intriguingly, the proband’s condition was exacerbated 
with fever. A link between fever and NaV1.5 function has 
been suggested earlier.7 The authors observed pronounced 
acceleration of NaV1.5 activation and fast inactivation kinet-
ics with increased temperature. They also performed cardiac 
action potential modeling experiments, indicating a shorten-
ing of cardiac action potential on fever-induced effect on INa 
function.
Proband 2 had a novel NaV1.5 S1218I mutation. S1218I is a 
novel mutation in the DIII/S1, resulting in a nonconservative 
substitution of a small, polar, hydrophilic serine highly con-
served through evolution with a larger, nonpolar, hydropho-
bic isoleucine. In silico analysis (Polyphen-2)19 predicted that 
S1218I will be damaging. In line with this, the homozygous 
NaV1.5 S1218I had complete loss of function and 50% rescue 
of the phenotype in the heterozygous state without affecting 
the biophysical kinetic parameters. The fact that 1 point muta-
tion in the homozygous state abolished the sodium current and 
the fact that the heterozygous state kinetics were similar to 
WT but with 50% reduction in peak sodium current density, 
favor a trafficking defect rather than activation or inactivation 
gating kinetic defects. Several mutations affecting the DIII of 
NaV1.5 have been described in BrS (S1219N and E1225K).17
We have identified and characterized the function of 2 
novel SCN5A mutations that resulted in partial (R811H) and 
complete loss of function of INa (S1218I). The variable phe-
notypic range of SCN5A mutations shows the importance of 
sodium channel regulation in maintaining normal rhythm. 
Furthermore, different mutations in SCN5A have different 
impact on INa aiding the risk assessment of unaffected at-risk 
family members. The pedigree of proband had 2 SCN5A muta-
tions, but our work showed that the R811H led to the Brugada 
phenotype, whereas the R620H was not pathogenic. Although 
heterologous expression system for voltage-clamp studies is 
an approximation of NaV1.5 function in human cardiomyo-
cytes, this system has been instrumental over the years in 
understanding how SCN5A variants affect arrhythmogenicity.
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Figure 6. Electrophysiological characterization of R620H. 
A, Representative whole-cell current recordings for NaV1.5 wild 
type (WT; n=7) and R620H (n=6) transiently expressed in Chinese 
hamster ovary-K1 cells. Currents were activated by the depicted 
voltage-clamp protocol. B, Peak current density plotted as a 
function of voltage.
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Figure 7. Mimicking the compound heterozygous condition 
of proband 1. Peak current densities for NaV1.5 wild type (WT; 
n=6) and R620H+R811H (n=7) transiently expressed in Chinese 
hamster ovary-K1 cells. Currents were activated as in Figures 3 
and 6.
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Conclusions
We describe 2 novel SCN5A mutations that result in partial 
and complete loss of function of INa. These findings have an 
important clinical significance and implications by elucidat-
ing how different mutations in SCN5A have different impact 
on INa and help in the risk assessment of unaffected at-risk 
family members.
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Figure 8. Electrophysiological character-
ization of S1218I. A, Representative  
whole-cell current recordings for NaV1.5 
wild type (WT), WT expressed with 
S1218I (1:1 ratio), and S1218I transiently 
expressed in Chinese hamster ovary-
K1 cells. Currents were activated by the 
depicted voltage-clamp protocol. B, Peak 
current density plotted as a function of 
voltage, demonstrating a complete loss of 
function for S1218I.
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CLINICAL PERSPECTIVE
In our study, we identified novel mutations in SCN5A in patients diagnosed with Brugada syndrome. Of note, 1 proband 
carried 2 different mutations. Although it is established that mutations in the cardiac sodium channel are associated with 
Brugada syndrome, there is increasing evidence for the impact of the individual genetic background of a patient. Specifically, 
other rare or frequent variants may play an important role in the clinical expression of a disease. Our in-depth electrophysi-
ological characterization of each variant shows that these novel mutations result in partial and complete loss of function of 
INa, respectively. These findings have clinical implications, in that different mutations in SCN5A have different effects on INa. 
Dissecting the individual functional phenotype may aid the risk assessment of unaffected at-risk family members.
 by guest on February 20, 2013circep.ahajournals.orgDownloaded from 
